Neutrophil elastase cleavage of human factor IX generates an activated factor IX-like product devoid of coagulant function

Blood

Volumn 92, Issue 4, 1998, Pages 1287-1296

  Samis, John A ^a   Kam, Eunice ^a   Nesheim, Michael E ^a   Giles, Alan R ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 9; HEPARIN; LEUKOCYTE ELASTASE; THROMBIN;

ARTICLE; BLOOD CLOTTING; HEMOSTASIS; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; REGULATORY MECHANISM;

EID: 0032529289     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.4.1287     Document Type: Article

References (37)

1. Davie EW, Ratnoff OD: Waterfall sequence for intrinsic blood clotting. Science 145:1310, 1964
2. Lundblad RL, Kingdon HS, Mann KG: Thrombin, in Lorand L (ed): Methods in Enzymology. New York, NY, Academic, 1976, p 156
3. Giles AR, Mann KG, Nesheim ME: A combination of factor Xa and phosphatidylcholine-phosphatidylserine vesicles bypasses factor VIII in vivo. Br J Haematol 69:491, 1988
4. Hoogendoorn H, Nesheim ME, Giles AR: A qualitative and quantitative analysis of the activation and inactivation of protein C in vivo in a primate model. Blood 75:2164, 1990
5. Giles AR, Nesheim ME, Herring SW, Hoogendoorn H, Stump DC, Heldebrant CM: The fibrinolytic potential of the normal primate following the generation of thrombin in vivo. Thromb Haemost 63:476, 1990
6. Giles AR, Nesheim ME, Mann KG: Studies of factors V and VIII:C in an animal model of disseminated intravascular coagulation. J Clin Invest 74:2219, 1984
7. Hoogendoorn H, Weitz JI, Giles AR: Evidence for the generation of elastase activity in a primate model of disseminated intravascular coagulation (DIC). Thromb Haemost 69:1127, 1993 (abstr)
8. Pieters J, Willems G, Hemker HC, Lindhout T: Inhibition of factor IX(a) and factor X(a) by antithrombin III/heparin during factor X activation. J Biol Chem 263:15313, 1988
9. Takaki A, Enfield DL, Thompson AR: Cleavage and inactivation of human factor IX by granulocyte elastase. J Clin Invest 72:1706, 1983
10. Anson DS, Choo KH, Rees DJG, Giannelli F, Gould K, Huddleston JA, Brownlee GG: The gene structure of human antihaemophilic factor IX. EMBO J 3:1053, 1984
11. Bajaj SP, Rapaport SI, Russell WA: Redetermination of the rate-limiting step in the activation of factor IX by factor XIa and by factor VIIa/tissue factor. Biochemistry 22:4047, 1983
12. Reiner AP, Davie EW: The physiology and biochemistry of factor IX, in Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD (eds): Haemostasis and Thrombosis. Edinburgh, UK Churchill Livingstone, 1994, p 309
13. Lenting PJ, ter Maat H, Clijsters PPFM, Donath M-JSH, Van Mourik JA, Mertens K: Cleavage at Arginine 145 in human blood coagulation factor IX converts the zymogen into a factor VIII binding enzyme. J Biol Chem 270:14884, 1995
14. Lenting PJ, Donath M-JSH, Van Mourik JA, Mertens K: Identification of a binding site for blood coagulation factor IXa on the light chain of human factor VIII. J Biol Chem 269:7150, 1994
15. Lawson JH, Mann KG: Cooperative activation of human factor IX by the human extrinsic pathway of blood coagulation. J Biol Chem 266:11317, 1991
16. Bajaj SP, Rapaport SI, Maki St, Brown SF: A procedure for the isolation of human protein C and protein S as by-products of the purification of factors VII, IX, X and prothrombin. Prep Biochem 13:191, 1983
17. Barenholz Y, Gibbs D, titman BJ, Goll J, Thompson D, Carlson FD: A simple method for the preparation of homogeneous phospholipid vesicles. Biochem J 16:2806, 1977
18. Hoogendoorn H, Cerskus A, Ofosu F, Blajchman M, Hirsh J: Preparation and partial characterization of human plasma depleted of antithrombin-III by heparin-sepharose affinity chromatography. Thromb Res 20:77, 1980
19. Proctor RR, Rapaport SI: The partial thromboplastin time with kaolin; a simple screening test for first-stage plasma clotting factor deficiencies. Am J Clin Pathol 36:212, 1961
20. Neville DM: Molecular weight determination of protein-dodecyl sulfate complexes by gel electrophoresis in a discontinuous buffer system. J Biol Chem 246:6328, 1971
21. Lin S-W, Lin C-N, Hamaguchi N, Smith KJ, Shen M-C: Characterization of a factor IX variant with a Glycine207 to Glutamic acid mutation. Blood 84:1866, 1994
22. Lottenberg R, Jackson CM: Solution composition dependent variation in extinction coefficients for p-Nitroaniline. Biochim Biophys Acta 742:558, 1983
23. Geddes VA, Le Bonniec BF, Louie GV, Braver GD, Thompson AR, MacGillivray RTA: A moderate form of hemophilia B is caused by a novel mutation in the protease domain of factor IX. J Biol Chem 264:4689, 1989
24. Rizza CR: Haemophilia and related inherited coagulation defects, in Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD (eds): Haemostasis and Thrombosis. Edinburgh, UK, Churchill Livingstone, 1994, p 819
25. Thompson AR: Radioimmunoassay of factor IX in the hemophilias. Methods Hematol 5:122, 1982
26. Travis J: Structure, function, and control of neutrophil proteinases. Am J Med 84(6A):37, 1988
27. Enfield DL, Thompson AR: Cleavage and activation of human factor IX by serine proteases. Blood 64:821, 1984
28. Brandstetter H, Bauer M, Huber R, Lollar P, Bode W: X-ray structure of clotting factor IXa: Active site and module structure related to Xase activity and hemophilia B. Proc Natl Acad Sci USA 92:9796, 1995
29. van Dieijen G, Van Rijn JLML, Govers-Riemslag JWP, Hemker HC, Rosing J: Assembly of the intrinsic factor X activating complex -Interactions between factor IXa, factor VIIIa and phospholipid. Thromb Haemost 53:396, 1985
30. Bertina RM, van der Linden IK, Mannucci PM, Reinalda-Poot HH, Cupers R, Poort SR, Reitsma PH: Mutations in hemophilia Bm occur at the ARG(180)-Val activation site or in the catalytic domain of factor IX. J Biol Chem 265:10876, 1990
31. Taylor SAM, Liddell MB, Peake IR, Bloom AL, Lillicrap DP: A mutation adjacent to the beta cleavage site of factor IX (valine 182 to leucine) results in mild haemophilia Bm. Br J Haematol 75:217, 1990
32. Liddell MB, Peake IR, Taylor SAM, Lillicrap DP, Giddings JC, Bloom AL: Factor IX Cardiff: A variant factor IX protein that shows abnormal activation is caused by an arginine to cysteine substitution at position 145. Br J Haematol 72:556, 1989
33. Noyes CM, Griffith MJ, Roberts HR, Lundblad RL: Identification of the molecular defect in factor IX-Chapel Hill: Substitution of histidine for arginine at position 145. Proc Natl Acad Sci USA 80:4200, 1983
34. Okajima K, Fujise R, Motosato Y, Ushijima M, Okabe H, Takatsuki K: Plasma levels of granulocyte elastase-alpha 1 protease inhibitor complex in patients with disseminated intravascular coagulation: Pathophysiologic implications. Am J Hematol 47:82, 1994
35. Padrines M, Bieth JG: Elastin decreases the efficiency of neutrophil elastase inhibitors. Am J Respir Cell Molec Biol 4:187, 1991
36. Bangalore N, Travis J: Comparison of properties of membrane bound versus soluble forms of human leukocytic elastase and cathepsin G. Biol Chem Hoppe-Seyler 375:659, 1994
37. Samis JA, Garrett M, Manuel RP, Nesheim ME, Giles AR: Human neutrophil elastase activates factor V then subsequently inactivates the activated product. Blood 90:1065, 1997